Glutamine metabolism and radiosensitivity: Beyond the Warburg effect

Ryan S. Alden, Mohammad Zahid Kamran, Bassel A. Bashjawish and Brittany A. Simone*

Radiation Oncology Department, State University of New York (SUNY) Upstate Medical University, Syracuse, NY, United States

Mounting data suggest that cancer cell metabolism can be utilized therapeutically to halt cell proliferation, metastasis and disease progression. Radiation therapy is a critical component of cancer treatment in curative and palliative settings. The use of metabolism-based therapeutics has become increasingly popular in combination with radiotherapy to overcome radioresistance. Over the past year, a focus on glutamine metabolism in the setting of cancer therapy has emerged. In this mini-review, we discuss several important ways (DNA damage repair, oxidative stress, epigenetic modification and immune modulation) glutamine metabolism drives cancer growth and progression, and present data that inhibition of glutamine utilization can lead to radiosensitization in preclinical models. Future research is needed in the clinical realm to determine whether glutamine antagonism is a feasible synergistic therapy that can be combined with radiotherapy.

KEYWORDS
cancer, glutamine (Gln), radiation, metabolism, radiosensitivity, telaglenastat, sirpiglenastat, immunotherapy

1 Introduction

Nearly 100 years ago, Otto Warburg demonstrated that cancer utilized more glucose and released more lactate than normal tissue under aerobic conditions (1). The understanding of altered metabolism as a cancer hallmark has accelerated in the last two decades (2, 3). More than 50% of cancer patients will receive radiation therapy, and improving response to therapy and decreasing toxicity is vital (4). There is growing interest in leveraging cancer metabolism to expand the therapeutic window. Calorie and carbohydrate restriction increase sensitivity to radiation in vitro and in vivo, but adoption in clinical trials has been slow (5), perhaps because weight loss is associated with poor cancer outcomes (5–9). Liu et al. recently summarized preclinical and early clinical studies regarding radiosensitization through inhibition of lactate metabolism (10). Over the last year, glutamine metabolism has continued to emerge as another important driver
of resistance to anti-cancer therapies including radiation. Glutamine metabolism and transport plays a role in DNA damage repair (DDR), oxidative stress, epigenetic modification and immunosuppression. It thereby promotes tumor survival, growth and dissemination in addition to radioresistance. This mini-review summarizes recent investigations of glutamine manipulation for radiosensitization and anti-cancer therapy.

1.1 Glutamine in DNA damage repair and oxidative stress

Glutamine is critical to tumor metabolism and therefore is an attractive target for potential therapeutics (Figure 1). It contributes to DDR after ionizing radiation (IR) as a vital part of nucleotide synthesis (12). In addition, conversion of glutamine to glutathione via leads to increased capacity for DDR through free radical scavenging (12). As such, there are multiple small molecule inhibitors being investigated as potential radiosensitizers. These include V-9302, which antagonizes the c-Myc-regulated amino acid transporter ASCT2, as well as glutaminase (GLS) inhibitor CB-839. JHU083, a prodrug of the broad glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON), disrupts NADP(H) and redox homeostasis in cancer cells, while decreasing hypoxia, a well-known contributor to radioresistance (13–15). Lastly, depletion of glutamine as a conditionally essential amino acid with the use of L-asparaginase (L-ASP) has been attempted as a means to induce cell cycle arrest and increase radiosensitivity (16, 17).

To date, several preclinical studies have been published utilizing CB-839 (Telaglenastat) to sensitize different cancers to IR (18, 19). Rashmi et al. have demonstrated that the use of glutamine to glutathione via leads to increased capacity for DDR through free radical scavenging (12). As such, there are multiple small molecule inhibitors being investigated as potential radiosensitizers. These include V-9302, which antagonizes the c-Myc-regulated amino acid transporter ASCT2, as well as glutaminase (GLS) inhibitor CB-839. JHU083, a prodrug of the broad glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON), disrupts NADP(H) and redox homeostasis in cancer cells, while decreasing hypoxia, a well-known contributor to radioresistance (13–15). Lastly, depletion of glutamine as a conditionally essential amino acid with the use of L-asparaginase (L-ASP) has been attempted as a means to induce cell cycle arrest and increase radiosensitivity (16, 17).

To date, several preclinical studies have been published utilizing CB-839 (Telaglenastat) to sensitize different cancers to IR (18, 19). Rashmi et al. have demonstrated that the use of glutamine to glutathione via leads to increased capacity for DDR through free radical scavenging (12). As such, there are multiple small molecule inhibitors being investigated as potential radiosensitizers. These include V-9302, which antagonizes the c-Myc-regulated amino acid transporter ASCT2, as well as glutaminase (GLS) inhibitor CB-839. JHU083, a prodrug of the broad glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON), disrupts NADP(H) and redox homeostasis in cancer cells, while decreasing hypoxia, a well-known contributor to radioresistance (13–15). Lastly, depletion of glutamine as a conditionally essential amino acid with the use of L-asparaginase (L-ASP) has been attempted as a means to induce cell cycle arrest and increase radiosensitivity (16, 17).

To date, several preclinical studies have been published utilizing CB-839 (Telaglenastat) to sensitize different cancers to IR (18, 19). Rashmi et al. have demonstrated that the use of glutamine to glutathione via leads to increased capacity for DDR through free radical scavenging (12). As such, there are multiple small molecule inhibitors being investigated as potential radiosensitizers. These include V-9302, which antagonizes the c-Myc-regulated amino acid transporter ASCT2, as well as glutaminase (GLS) inhibitor CB-839. JHU083, a prodrug of the broad glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON), disrupts NADP(H) and redox homeostasis in cancer cells, while decreasing hypoxia, a well-known contributor to radioresistance (13–15). Lastly, depletion of glutamine as a conditionally essential amino acid with the use of L-asparaginase (L-ASP) has been attempted as a means to induce cell cycle arrest and increase radiosensitivity (16, 17).

To date, several preclinical studies have been published utilizing CB-839 (Telaglenastat) to sensitize different cancers to IR (18, 19). Rashmi et al. have demonstrated that the use of glutamine to glutathione via leads to increased capacity for DDR through free radical scavenging (12). As such, there are multiple small molecule inhibitors being investigated as potential radiosensitizers. These include V-9302, which antagonizes the c-Myc-regulated amino acid transporter ASCT2, as well as glutaminase (GLS) inhibitor CB-839. JHU083, a prodrug of the broad glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON), disrupts NADP(H) and redox homeostasis in cancer cells, while decreasing hypoxia, a well-known contributor to radioresistance (13–15). Lastly, depletion of glutamine as a conditionally essential amino acid with the use of L-asparaginase (L-ASP) has been attempted as a means to induce cell cycle arrest and increase radiosensitivity (16, 17).
CB-839 in PI3K-activated cervical cancers can independently affect cell survival in PTEN−/− cervical cancer cell lines (20). Additionally, it was demonstrated that the combination of CB-839 with radiation provides improved tumor control in SiHa xenograft tumors, suggesting that CB-839 works synergistically with radiotherapy in cervical cancer. Similarly, after identifying that increased tumor GLS mRNA levels were associated with decreased survival in The Cancer Genome Atlas' transcriptome database (p<0.03), Wicker et al. utilized CB-839 in combination with sublethal IR in a xenograft model of high GLS expressing, p16−/−, head and neck squamous cell carcinoma (21). Compared with control (vehicle treated) tumors, the size of radiation-treated, CB-839-treated and combination-treated tumors were 74.3%, 94.9% and 61.7%, respectively. Mechanistically, they showed that DNA damage assessed by γ-H2AX was significantly higher in combination-treated cells, and that this additive effect was reversible with N-acetyl-cysteine (21).

This concept is moving to the clinic in both cervical cancer and gliomas (Table 1). A phase I study investigating safety and tolerability of CB-839 with radiation and temozolomide in isocitrate dehydrogenase (IDH)-mutated grade II/III astrocytoma (NCT03528642) is currently active. The study will evaluate maximum tolerated dose and recommended phase II dose as primary outcomes as well as overall response rate (ORR) and clinical benefit rate as defined by Response Assessment in Neuro-Oncology (RANO) criteria. The same is being attempted in cervical cancer with NCT05521997, a randomized phase II trial of CB-839 in combination with cisplatin and radiation compared with standard chemoradiation. The primary endpoint in this study is progression-free survival at 24 months after therapy. Yang et al. and Lemberg et al. provide tables showing additional clinical trials involving CB-839 (17, 30).

Depleting extracellular glutamine with L-ASP provides another avenue of potential therapeutic benefit. Targeting extracellular glutamine circumvents the non-specificity and toxicity of glutamine uptake inhibitors (24, 31). Additionally, inhibition of one specific glutamine uptake receptor can lead to upregulation of alternate receptors, rendering these therapies ineffective. Thiruvalluvan et al. demonstrated that the use of L-ASP in prostate cancer leads to cell cycle arrest, thereby increasing sensitivity to DNA damage (22). Treatment of 22Rv1 cells with L-ASP lead to downregulation of CDK1, CCNB1 and PCNA with elevation of p21 in cells treated with radiation. In this study, a radioresistant prostate cancer cell line was created (ARCAPM−IR). Exposure to L-ASP sensitized these cells to radiation treatment compared with the parent line (ARCAPM) (22).

1.2 Alpha-ketoglutarate and the epigenetic landscape of tumors

Once transported intracellularly, glutamine can be trafficked to the mitochondria of cancer cells and metabolized to glutamate, which impacts production of alpha-ketoglutarate (AKG) through the tricarboxylic acid (TCA) cycle. This AKG is then transported out of the mitochondria and modifies expression of key proteins linked to cancer growth and progression. Histone and DNA methylation is directly affected by AKG (32, 33). It is by this process AKG is posited to affect stemness in cancer cells, and its concentration within cells can drive progression and metastasis. Tran et al. recently demonstrated that AKG promotes hypomethylation of DNA histone H3K4me3, which targets several Wnt pathway genes in colorectal cancer (33). Likewise, AKG affects radiosensitivity in the setting of IDH mutations. In IDH-mutated tumors, there is an abundance of AKG leading to accumulation of a by-product of the Krebs cycle, 2-hydroxyglutarate (2HG), which ultimately affects methylation of enzymes responsible for DNA double strand break (DSB) repair (34). This aberration in DSB repair leads to increased radiosensitivity as seen in IDH mutated gliomas (34, 35).

Histone and DNA methylation are directly affected by AKG levels through AKG-dependent enzymes including jumonji domain-containing histone demethylases and Tet proteins that modify DNA methylation. Mukha et al. demonstrate that the radiosensitivity of glutamine-dependent tumors such as prostate cancer can be manipulated through this pathway (36). Homologous recombination repair (HRR) aberrations have been linked to impaired histone demethylation by AKG-dependent dioxygenases KDM4A and KDM4B. It was hypothesized by Sulkowski et al. that H3K9 methylation is directly affected by 2HG, and that high concentrations of this metabolite cause impairment of DNA DSB localization (37). This ultimately implies that accumulation of 2HG in the context of radiation could cause sensitization through hypermethylation of H3K9 (37). This defect in HRR caused by 2HG accumulation mimics BRCA1/BRCA2 deficient tumors as it has been shown to sensitize cells to PARP inhibitors (37). In line with this concept, the function of KDMs as modulated by oncometabolites has been linked to radioresistance in lung cancer (38).

Taken together, inherent mutations of metabolic pathways in cancer cells such as IDH mutations as well as accumulation of oncometabolites such as AKG within tumors create a diverse metabolic tumor microenvironment (TME) that directly impacts DSB repair. This creates an opportunity to use these vulnerabilities to therapeutic advantage in combination with radiotherapy.

1.3 Glutamine and anticancer immunity

The interaction between radiotherapy and the immune system is complex and continues to be elucidated (39–44). Radiation promotes tumor immunogenicity through increased expression of chemokines such as CXCL9, CXCL10 and CXCL16 which lead to T-cell recruitment (40, 42, 43). Simultaneously, radiation leads to release of tumor antigens,
### TABLE 1  Selected preclinical studies and clinical trials exploring glutamine metabolism targets for cancer therapy.

#### Preclinical studies

| Target(s)                        | Inhibitor(s)                             | Model(s)                          | Selected Results                                                                 | Reference(s) |
|----------------------------------|------------------------------------------|-----------------------------------|----------------------------------------------------------------------------------|---------------|
| GLS, gamma-glutamylcysteine synthetase, thiorredoxin reductase | CB-839, BSO, AUR | CaSki, C33A, SiHa, SiHa PTEN knockout cervical cancer cell lines | CB-839 induced oxidative stress, reduced cell proliferation, viability and surviving fraction in CaSki and SiHa PTEN knockout cells, SiHa cells relatively resistant | Rashmi Mol Cancer Ther 2020 (20) |
| GLS                              | CB-839                                   | CAL-27, HNS, FaDu HNSCC cell lines | CB-839 & RT increased oxidative stress (8-oxoguanine) and DNA damage (γH2AX) in CAL-27 cells | Wicker Cancer Lett 2021 (21) |
| glutamine                        | L-ASP                                    | CWR22RV1, PC3, ARCaPM & ARCaPM-IR Pca cell lines: | CB-839 & RT reduced tumor volume in xenografts | Thiruvalluvan Cancers (Basel) 2022 (22) |
| GLS, PD-1, PD-L1                 | CB-839, anti-PD-1, anti-PD-L1            | Various Breast, NSCLC, lymphoma, myeloma, mesothelioma & ALL cell lines; CT26 colon cancer mouse model | CB-839 increases glutamine concentration and decreases glutamine metabolites in NSCLC cell lines, with minimal impact on T-cell activation or division | Gross Cancers Res 2016 (23) |
| GLS                              | CB-839, anti-CTLA4, anti-PD-1            | Melanoma: patient derived cell lines & TILs, A375HG cells, B16-F10 xenografts Yummer 1.7 mouse model | CB-839 in tumor cells cocultured with TILs increased cleaved caspase-3 | Varghese Mol Cancer Ther 2020 (24) |
| glutamine metabolism             | JHU083, anti-PD-1                        | mice models: MC38 & CT26 colon cancer, EL-4 lymphoma, B16 melanoma | decreased tumor growth & improved survival with JHU083 treatment in all models, with some complete responses & rejection of tumor re-challenge JHU083 pushes TILs to a long-lived, memory-like, proliferative and activated phenotype | Leone Science 2019 (13) |
| glutamine metabolism             | JHU083 (prodrug of DON), anti-CTLA4, anti-PD-1 | 4T1 triple-negative breast cancer model | JHU083 inhibits 4T1 tumor growth and metastasis; enhanced response to checkpoint blockade JHU083 reduced MDSCs, decreased secretion of MDSC recruitment & growth factors, reprogrammed TAMs to proinflammatory phenotype | Ob J Clin Invest 2020 (25) |
| glutamine metabolism             | DRP-104 (prodrug of DON), anti-PD-1, anti-PD-L1, anti-CTLA4 | CT26 & MC38 colon cancer models H22 hepatocellular cancer model | DRP-104 increased T, NK, NKT cells and M1-TAMs and decreased MDSCs; also inhibited tumor growth, led to durable responses and rejection of rechallenge | Yokoyama Mol Cancer Ther 2022 (26) |
|                                  |                                          |                                   |                                                                                  | Yokoyama J Immunother Cancer 2019 (27) |
|                                  |                                          |                                   |                                                                                  | Yokoyama Cancer Res 2020 (28) |

#### Clinical studies

| Target(s) | Treatment | Diagnosis | Status | Trial Number |
|-----------|-----------|-----------|--------|--------------|
| GLS       | CB-839 with RT and temozolomide | IDH-mutant astrocytoma grade II/III | Phase Ib trial: Active, not recruiting | NCT03528642 |
| GLS       | RT and cisplatin vs. CB-839 with RT and cisplatin | FIGO III-IV cervical cancer | Randomized Phase II trial: Not yet recruiting | NCT05521997 |
| GLS, PD-1 | CB-839 with nivolumab | Advanced melanoma, NSCLC with prior IO, Advanced RCC with or without prior IO | Phase I/II trial: recruitment completed 04/2020 | NCT02771626, Meric-Bernstam SITC 2017 (29) |

GLS, glutaminase; CB-839, telaglenastat; BSO, L-buthionine sulfoximine; AUR, Auranosin; RT, radiation therapy; HNSCC, head and neck squamous cell carcinoma; L-ASP, L-asparaginase; DON, 6-diazo-5-oxo-L-norleucine; NSCLC, non-small cell lung cancer; ALL, acute lymphoblastic leukemia; IO, immunotherapy; TIL, tumor infiltrating lymphocyte; MDSCs, myeloid derived suppressor cells; TAMs, tumor associated macrophages; DRP-104, sirpiglenastat; FIGO, Federation of Gynecology and Obstetric; RCC, renal cell carcinoma.
expression of death receptors, MHC class I proteins, and costimulatory molecules that facilitate T-cell-mediated killing of tumor cells (40, 44–46). Radiation also enhances PD-L1 expression, which holds T-cell reactivity in check (40, 47). Radiation can induce differentiation of Tregs and myeloid-derived suppressor cells (MDSCs), which hinder anti-tumor immunity (39, 40, 48). Radiation therapy also has mixed effects on the innate immune response, as it contributes to M1, pro-inflammatory anti-tumor macrophages, but also to M2, immunosuppressive and pro-tumor macrophages (39, 40).

Therefore, the ideal metabolic strategy for radiosensitization would also contribute to the anti-tumor immune response and ameliorate the immunosuppressive effects of radiation. Recent evidence suggests that inhibition of glutamine metabolism meets these objectives. Multiple authors have shown that inhibition of glutamine metabolism impacts glutamine-dependent tumor cells and immune cells differently, ultimately bolstering innate and adaptive anti-tumor response (13, 23–25, 29, 30).

### 1.3.1 Glutamine and T-cell activation

Glutamine metabolism plays an important role in T-cell activation and proliferation, as a precursor for biosynthesis and source of AKG for the TCA cycle and ATP production (17, 30, 49). Glutamine induces a dose-dependent increase in proliferation of stimulated T-cells in vitro (23, 24). On the surface therefore, it may seem that glutamine inhibition would frustrate anticancer immunity, but recent investigation shows otherwise.

Johnson et al. demonstrated that in effector T-cell populations with transient GLS deficiency, IL2 promotes Th1 phenotype and CD8 T-cell function, suggesting that inhibition of glutamine metabolism enhances an anti-tumor immune composition (24, 50). Aberrant tumor metabolism, which also upregulates glutamine metabolism for biosynthesis and anaplerosis, depletes glutamine in the tumor environment (13, 24, 30). Inhibition of GLS with CB-839, or of glutamine metabolism broadly with JHU083 or DRP-104 (Siriplegenastat, another pro-drug of DON), restores balance between tumor and T-cell glutamine utilization. Multiple authors have shown that CB-839, JHU083 and DRP-104 reduce tumor glutamine consumption and increase glutamine concentrations systemically and in the TME, providing T-cells with greater access to this conditionally essential amino acid (13, 17, 23, 24, 26, 29). CB-839 also has minimal impact on T-cell proliferation and acceptable toxicity profile, unlike the non-specific inhibitor DON (23, 24). Leone et al. found that JHU083 increased proliferation and activation markers in CD8+ T-cells in mice harboring MC38 colon cancer, and selective activation of this prodrug in the TME mitigates toxicity observed with DON (13).

Gross et al. demonstrated in a syngeneic CT26 colon cancer mouse model that combination CB-839 and anti-PD-1 or anti-PD-L1 therapy enhanced tumor regression and improved survival compared to control or monotherapy (23). These benefits were reversed with depletion of CD8+ T-cells from the tumors, supporting the hypothesis that GLS inhibition with CB-839 enhances CD8+ T-cell activity in the TME when administered with checkpoint inhibitors (23). These results led to the phase I/II trial CX-839-004; CB-839 with nivolumab in advanced melanoma, renal cell carcinoma (RCC), or non-small cell lung cancer. The trial completed recruitment in 2020. Preliminary results showed no toxicity above nivolumab alone, and three patients with melanoma and progression on prior immunotherapy achieved objective response (29).

Building on the potential to revitalize checkpoint inhibitor response in the pre-treated setting, Varghese et al. report promising preclinical results in treatment-naïve melanoma models (24). In mice vaccinated with melanoma-specific CD8+ T-cells and stimulatory molecules, CB-839 increased T-cell proliferation and activation compared to vehicle control (24). T-cell vaccination with CB-839 treatment led to the greatest decrease in B16 xenograft tumor growth vs. monotherapy or control. Mouse survival was 100% at 35 days in the combination group (24). These results suggest clinical study of GLS inhibition together with T-cell vaccines or other T-cell therapies is warranted.

Varghese et al. also tested CB-839 together with immune-checkpoint inhibitors in a BRAF V600E, high mutational burden melanoma model. Anti-PD-1 or anti-CTLA4 therapy inhibited tumor growth, in keeping with prior findings (24, 51). CB-839 monotherapy had no effect on tumor growth, but combination with anti-PD-1 or anti-CTLA4 showed synergistic effects, with triple therapy leading to apparent complete response at 29 days (24).

JHU083 also has shown exciting results, with improved tumor control and survival in mouse models of several tumor types (13). JHU083 with concurrent anti-PD-1 therapy in a MC38 mice showed complete response rate of ≥90%, compared to no complete responses with anti-PD-1 monotherapy (13). Lack of single-agent activity is a criticism some have leveled against CB-839 (13, 23, 52). In contrast, in one experiment, 2 of 5 mice with MC38 tumors had complete response to JHU083 monotherapy maintained ≥80 days after tumor injection (13). Additionally, 13 of 15 animals with complete response to JHU083 monotherapy rejected tumor upon rechallenge. These results indicate JHU083 may have single agent utility. As with the CB-839 experience above, depletion of T-cells demonstrated that JHU083 efficacy relied on CD8+ T-cell activity (13). Based on these data, along with RNA-seq and gene set enrichment analysis (GSEA) of tumor infiltrating lymphocytes (TILs), Leone et al. concluded that JHU083 pushes TILs toward a long-lived, memory-like, proliferative and highly activated effector phenotype (13, 17).

DRP-104 produced similar results in mice harboring colon and hepatocellular model tumors (26–28, 30). Yokoyama et al. found that DRP-104 tumor growth inhibition at day 12 in CT26-bearing mice was 48% with anti-PD-1, 90% with DRP-104 and 94% with combination (26, 27). In MC38-bearing mice, DRP-104 monotherapy led to growth inhibition of 96-101% and increase in median survival from 13 days with vehicle control...
Alden et al.

1.3.2 Glutamine and M2 macrophages

While cancer cell metabolism hoards nutrients such as glutamine, the TME is further stripped of resources by the activity of M2 macrophages and MDSCs. Tumor-associated macrophages (TAMs) contribute to cancer progression and metastasis by promoting angiogenesis, invasion, motility, intravasation and extravasation, while also curating an immunosuppressive environment (25, 39, 53, 54). M2 TAMs and MDSCs express immune checkpoint molecules like PD-L1 to attenuate T-cell response, and metabolic enzymes which deplete nutrients and smother T-cell proliferation. Oh et al. report the inhibition of glutamine metabolism with JHU083 promoted generation of antitumor, proinflammatory TAMs and reduced generation and recruitment of MDSCs (25).

4T1 is a triple-negative breast cancer model that is resistant to immune checkpoint blockade due to abundant suppressive TAMs and MDSCs (25, 55). JHU083 showed significant inhibition of 4T1 tumor growth in mice compared with vehicle, anti-PD1, anti-CTLA4 or combination checkpoint blockade (25). JHU083 also significantly inhibited lung metastasis. JHU083 enhanced checkpoint blockade activity in EO771 immunotherapy-sensitive tumors, and sensitized 4T1 immunotherapy-resistant tumors to checkpoint blockade (25).

Oh et al. demonstrated that modulation of TAMs and MDSCs is responsible for these effects. JHU083 decreased MDSCs at the primary tumor site and in the lungs (common metastatic site). This was accompanied by decreased MDSC recruitment and growth factors such as M-CSF, GM-CSF and G-CSF. Finally, Oh et al. found through RNA-seq and GSEA that JHU083 reprogrammed TAMs promoting an M1, antitumor phenotype via down regulation of immunosuppressive genes such as Il10 and Nos2, with upregulation of lysosome, Toll-like receptor and proinflammatory gene transcription.

These data suggest broad glutamine antagonism with JHU083 or DRP-104 may increase radiosensitivity by favoring an antitumor immune response, but clinical study including combination with radiation is necessary.

1.3.3 Sequencing of combination therapy

Sequencing of immunotherapy and radiotherapy is an area of ongoing research; full exploration of this topic is beyond the scope of this mini-review (56, 57). Optimal timing depends on the mechanism of immunotherapy agent used and the fraction size of radiation (57). Notably, secondary analysis of KEYNOTE-001 found a survival benefit with pembrolizumab in patients previously treated with radiotherapy vs no prior radiotherapy (56, 58). As such, several clinical studies have specified immunotherapy within 3-84 days after radiation (59–61). Radiation can begin before, during or after immunotherapy in the ongoing A082002 trial in metastatic NSCLC, as long as it begins within 60 days of registration (NCT04929041). We hypothesize that radiation followed by or concurrent with immunotherapy, rather than starting with immunotherapy, will lead to optimal results by exposing tumor antigens and utilizing radiation-induced increase in PD-L1 expression to fuel immunotherapy response (56, 62). This hypothesis seems to be supported by the survival benefit from pembrolizumab after radiation in the PEMBRO-RT trial, but only in patients with negative PD-L1 at baseline, where perhaps PD-L1 expression was induced by radiation (59).

Adding glutamine antagonists leaves additional uncertainty regarding the best sequence, but Leone et al. report that “concurrent, not sequential” administration of JHU083 and anti-PD-1 was most effective (13). Most pre-clinical and clinical studies have initiated glutamine antagonists concomitantly with immunotherapy (23–25, 29), others have used concomitant and sequential approaches without direct comparison of the two (24, 27, 28). Wicker et al. introduced CB-839 two days before radiating HNSCC cells (21).

1.4 Personalized medicine: Identifying glutamine-dependent tumors that may benefit from inhibition of glutamine metabolism

Multiple cancer subtypes appear to be sensitive to glutamine inhibition. Gross et al. show cell death at glutamine deficit and dose-dependent growth enhancement with increasing glutamine concentrations in breast cancer, NSCLC, lymphoma, myeloma, mesothelioma and ALL cell lines (23). Sensitivity to glutamine metabolism in cervical cancer, melanoma, RCC, IDH-mutant glioma, HNSCC, colon cancer and hepatocellular cancer has been demonstrated by other authors discussed in this review (Table 1) (13, 17–30, 34, 30). One might hypothesize that PTEN-mutated endometrial cancers and IDH-mutant AML are sensitive given their genotype (63, 64). However, not all tumors are addicted to glutamine metabolism, and Yuneva
et al. point out “the metabolic profile of tumors depends on both the responsible genetic lesion and tissue type” (65). MYC-driven liver tumors are dependent on glutamine catabolism, while MET-driven liver tumors are not dependent on glutamine catabolism (65). Davidson et al. found that Kras G12D NSCLCs were not dependent on glutamine metabolism (52). Therefore, an understanding of what tumors may be sensitive to glutamine inhibition must look beyond simply the tissue of origin. Patient-derived xenograft experiments that incorporate sequencing or immunohistochemistry may be required to understand which tumors are ultimately sensitive and provide personalized cancer care.

2 Discussion

Glutamine metabolism contributes to cancer growth, progression and resistance to therapy. As a key player in DNA repair, epigenetic modification and reduction in oxidative stress, glutamine metabolism in cancer cells also increases radioresistance. Furthermore, glutamine use in cancer cells, TAMs and MDSCs contributes to an immunosuppressive TME which decreases the efficacy of immunotherapy and radiotherapy. Inhibition of glutamine metabolism increases oxidative stress in cancer cells, sensitizes radioresistant tumors to radiation in vitro and in vivo (18–20) and enhances innate and adaptive anti-tumor immunity (13, 17, 23, 25, 27–29, 50). Recent reports disclose several avenues for leveraging inhibition of, or abnormalities in, glutamine metabolism to widen the therapeutic window for anti-cancer therapy including radiotherapy (13, 17–21, 23–30, 34, 50). This approach seems most promising in tumors with high GLS expression such as some p16-negative HNSCC (21), DNA repair deficit such as IDH-mutant glioma (19, 34), or PTEN mutation/PI3K activation (20). Specifically, we anticipate combination with CB-839 will enhance the efficacy of standard of care chemoradiation in IDH-mutant GII/III astrocytoma (19, 34). CB-839 will likely increase DNA damage from increased oxidative stress and cause further impairment of DNA repair leading to enhanced tumor killing (19, 35). We also hypothesize CB-839 in combination with chemoradiation will improve outcomes in cervical cancer, particularly in PTEN mutant/PI3K activated cancers (20). By extension, the combination of CB-839 and radiation may also improve outcomes if studied in endometrial cancer, which can also harbor PTEN mutations (63). There may also be hope for radiosensitizing classically radioresistant cancers such as RCC through concurrent radiation and CB839, JHU083 or DRP-104 (29). Enhancing the radiosensitivity of these tumors may allow for deescalation of radiotherapy dose and reduced toxicity. Further combination with immunotherapy is also an attractive avenue, with optimal sequence of therapies an ongoing area of research (56, 57).

Ultimately, additional clinical research is necessary to determine feasibility and efficacy in combination with radiotherapy, and to determine which drug for targeting the glutamine pathway yields optimal clinical results (17).

Author contributions

RA, MK, BB, and BS, drafting the article, critical revision of the article, and final approval of the version to be published. BS, conception or design of the work. All authors contributed to the article and approved the submitted version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Warburg O, Posener K, Negelein E. Über den stoffwechsel der carcinomzelle. Biochem Zeitschr (1924) 152:309–44.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell (2000) 100(1):57–70. doi: 10.1016/S0092-8674(00)81683-9
3. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell (2011) 144(5):646–74. doi: 10.1016/j.cell.2011.02.013
4. Delaney G, Jacob S, Featherstone C, Burton M. The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer (2006) 104(6):1129–37. doi: 10.1002/cncr.21324
5. Icard P, Ollivier L, Forgez P, Otz J, Alfano M, Fournel L, et al. Perspective: Do fasting, caloric restriction, and diets increase sensitivity to radiotherapy? a literature review. Adv Nutr (2020) 11(5):1089–101. doi: 10.1093/advances/nmaa062
6. Tsang NM, Pai PC, Chung CC, Chuang WC, Tseng CK, Chang KP, et al. Overweight and obesity predict better overall survival rates in cancer patients with distant metastases. Cancer Med (2016) 5(4):665–75. doi: 10.1002/cam4.634
7. Gannavarapu BS, Lau SKM, Carter K, Cannon NA, Gao A, Ahn C, et al. Prevalence and survival impact of pretreatment cancer-associated weight loss: A
51. Wang J, Perry CJ, Meeth K, Thakral D, Damsky W, Micic V, et al. UV-induced somatic mutations elicit a functional T cell response in the Yummer1.7 mouse melanoma model. Pigment Cell Melanoma Res (2017) 30(4):428–35. doi: 10.1111/pcmr.12591
52. Davidson SM, Papagiannakopoulou T, Olenchock BA, Heyman JE, Kiebler MA, Luengo A, et al. Environment impacts the metabolic dependencies of ras-driven non-small cell lung cancer. Cell Metab (2016) 23(3):517–28. doi: 10.1016/j.cmet.2016.01.007
53. Noy R, Pollard JW. Tumor-associated macrophages: From mechanisms to therapy. Immunity (2014) 41(1):49–61. doi: 10.1016/j.immuni.2014.06.010
54. Qian B-Z, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 141(1):39–51. doi: 10.1016/j.cell.2010.03.014
55. Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blesser RL, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci USA (2014) 111(32):11774–9. doi: 10.1073/pnas.140626111
56. Lubas MJ, Kumar SS. The combined use of sbt and immunotherapy—a literature review. Curr Oncol Rep (2020) 22(12):117. doi: 10.1007/s11912-020-00986-9
57. Aliru ML, Schoenhals JE, Venkatesulu BP, Anderson CC, Barsoumian HB, Younes AJ, et al. Radiation therapy and immunotherapy: What is the optimal timing or sequencing? Immunotherapy (2018) 10(4):299–316. doi: 10.2217/intm-2017-0082
58. Shaverdian N, Lisberg AE, Bornaayyan K, Veruttipong D, Goldman JW, Formenti SC, et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-Small-Cell lung cancer: A secondary analysis of the keynote-001 phase 1 trial. Lancet Oncol (2017) 18(7):895–903. doi: 10.1016/S1470-2045(17)30380-7
59. Theelen WSME, Peuten HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJ, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: Results of the pembro-rt phase 2 randomized clinical trial. JAMA Oncol (2019) 5(9):1276–82. doi: 10.1001/jamaoncol.2019.1478
60. Bauml JM, Miek R, Ciunci C, Aggarwal C, Davis C, Evans T, et al. Pembrolizumab after completion of locally ablative therapy for oligometastatic non-small cell lung cancer a phase 2 trial. JAMA Oncol (2019) 5(9):1283–90. doi: 10.1001/jamaoncol.2019.1449
61. Seung SK, Curti BD, Crittenden M, Walker E, Coffey T, Siebert JC, et al. Phase 1 study of stereotactic body radiotherapy and Interleukin-2–tumor and immunological responses. Sci Transl Med (2012) 4(137):137ra74. doi: 10.1126/scitranslmed.3003649
62. Yoneda K, Kuvata T, Kanayama M, Mori M, Kawanami T, Yatera K, et al. Alteration in tumoural pd-L1 expression and stromal Cd8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer. Br J Cancer (2019) 121(6):490–6. doi: 10.1038/s41416-019-0541-3
63. Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB, et al. Clinical assessment of pten loss in endometrial carcinoma: Immunohistochemistry out-performs gene sequencing. Mod Pathol (2012) 25(5):699–708. doi: 10.1038/modpathol.2011.208
64. Liu X, Gong Y. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia. Biomark Res (2019) 7:22. doi: 10.1186/s40364-019-0173-z
65. Yuneva MO, Fan TWM, Allen TD, Higashi RM, Ferraris JV, Tsukamoto T, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab (2012) 15(2):157–70. doi: 10.1016/j.cmet.2011.12.015